Accanito Therapeutics
PrivateLast Round
Grant
Dec 2, 2021
Company Overview
Accanito Therapeutics is an oncology company that develops mitochondria-targeted therapies to selectively eliminate cancer cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accanito Therapeutics Comparables
Compare Accanito Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bantam Pharmaceutical | 83% | |
| SmartinBio Co., Ltd. | 82% | |
| MitoTax s.r.o. | 81% | |
Accanito Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 2, 2021 |
Accanito Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| U.S. Army Medical Research and Development Command | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 2, 2021
Received funding from Gateway for Cancer Research, National Cancer Institute, and U.S. Army.
Accanito Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Accanito Therapeutics's valuation, stock price, and market status.